Zydus Pharmaceuticals (United States)

Recent papers from Zydus Pharmaceuticals (United States)

1. A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell DiseaseEuropean Journal Of Haematology · 2026
2. Abstract PS1-13-15: A new FDA approved docetaxel + albumin formulation for breast cancer treatmentClinical Cancer Research · 2026
3. A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular DegenerationOphthalmology and Therapy · 2026
4. Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal ImpairmentClinical Pharmacology & Therapeutics · 2024
5. Advancing pediatric drug development in South Asia: Current landscape and vision for the futureIndian Journal of Pharmacology · 2024
6. Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic ImpairmentClinical Pharmacology in Drug Development · 2023
7. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic SyndromesClinical Pharmacology in Drug Development · 2023
8. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipientsLiver Transplantation · 2023
9. A Food‐Effect Study to Evaluate the Oral Bioavailability of DesidustatClinical Pharmacology in Drug Development · 2022
10. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)Clinical Pharmacology in Drug Development · 2022